Ascendis Pharma A/S Sponsored ADR (ASND) Stock: News, Analysis, Q&A, and Insights

Investment Analysis Report: ASND

Overview

ASND is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $8.49 billion. The company's industry focus is on Pharmaceuticals: Major. In this report, we will conduct a comprehensive analysis of ASND's financial statements over the past three years to evaluat...

Technical Analysis of ASND 2024-07-18

Overview

Analyzing the recent technical indicators for ASND provides a comprehensive view of its potential price movements in the coming days. The data reflects a mix of bullish and bearish signals, indicating a complex market environment. By examining trend, momentum, volatility, and volume indicators, we can derive insights that may guide futu...

Recent News & Updates

2024-07-24 09:33
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year(Simply Wall St.)
2024-07-07 09:01
2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect(TipRanks)
2024-07-05 09:58
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada(MT Newswires)
2024-07-05 06:33
Pendopharm and Ascendis to distribute hypoparathyroidism treatment(Pharmaceutical Technology)
2024-07-04 12:48
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada(CNW Group)
2024-06-25 07:11
TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target(MT Newswires)
2024-06-24 16:45
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024(GlobeNewswire)
2024-06-24 04:45
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024(Globenewswire)
2024-06-21 01:02
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand(Insider Monkey)
2024-06-20 13:02
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand(Insidermonkey)
2024-06-04 16:01
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference(GlobeNewswire)
2024-06-04 04:01
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference(Globenewswire)
2024-06-03 16:34
Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial(MT Newswires)
2024-06-03 16:01
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024(GlobeNewswire)
2024-06-03 04:01
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024(Globenewswire)
2024-05-31 09:26
Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target(MT Newswires)
2024-05-30 08:30
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024(GlobeNewswire)
2024-05-29 20:30
Ascendis to Spotlight Latest Updates for TransCon Rare Endocrinology Disease Portfolio at ENDO 2024(Globenewswire)
2024-05-15 13:57
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months(Benzinga)
2024-05-15 10:44
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing(Zacks)
2024-05-14 22:44
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing(Zacks)
2024-05-14 16:07
US Equity Markets Close Higher Tuesday as Producer Prices Rise(MT Newswires)
2024-05-14 15:20
Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop(MT Newswires)
2024-05-14 14:47
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy(Reuters)
2024-05-14 14:38
FDA extends review of Ascendis Pharma's hormone disorder therapy(Reuters)
2024-05-14 14:31
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism(GlobeNewswire)
2024-05-14 02:31
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism(Globenewswire)
2024-05-13 09:29
Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH(MT Newswires)
2024-05-13 08:30
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial(GlobeNewswire)
2024-05-12 20:30
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial(Globenewswire)

Page 1 of 7

previousnext

ASND

Performance

Profile

Investment Analysis Report: ASND

Overview

Technical Analysis of ASND 2024-07-18

Overview

Recent News & Updates